Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
deals
8
×
ipo
8
×
life sciences
national blog main
national top stories
san francisco blog main
8
×
cancer
new york blog main
san diego blog main
san diego top stories
san francisco top stories
boston top stories
new york top stories
startups
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
eli lilly
novartis
takeda pharmaceutical
venture capital
amgen
biogen
cancer immunotherapy
clinical trials
crispr
What
bio
roundup
drugs
ipo
medicines
pharmaceutical
cancer
deal
drug
gene
life
millions
new
plans
raise
science
typically
acquisitions
advance
aiming
alzheimer’s
ambys
announced
appetite
bails
becker
big
billions
biology
biotech
black
brand
bread
bridgebio
butter
buyout
capital
car
cash
ceo
Language
unset
Current search:
ipo
×
deals
×
" san francisco blog main "
×
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
4 years ago
Bio Roundup: Michael Becker, Suzanne Eaton, Gene Therapy Moves & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
Bio Roundup: #JPM19 Notes, Loxo Buyout, Black Diamond’s Cash & More
@xconomy.com
5 years ago
Synthorx Files for IPO to Advance Enhanced Cytokine Drugs
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?